ライフサイエンスコーパス: weakness

1 Het mice are growth-retarded and have muscle weakness.

2 pasticity, exaggerated reflexes and muscular weakness.

3 nsmission characterized by fatiguable muscle weakness.

4 in ameliorating skeletal muscle wasting and weakness.

5 d longest follow-up study of functional limb weakness.

6 one, underlies chronic sepsis-induced muscle weakness.

7 cterized by loss of skeletal muscle mass and weakness.

8 Axial weakness is greater than limb weakness.

9 energy expenditure, walking limitations, and weakness.

10 ere were 659 people with upper limb onset of weakness.

11 s with focal or asymmetric muscle atrophy or weakness.

12 contributor to intensive care unit acquired weakness.

13 multisystem disease with progressive muscle weakness.

14 rily by motor neuron degeneration and distal weakness.

15 ble to correct growth retardation and muscle weakness.

16 ill patients who do not develop ICU-acquired weakness.

17 n hyposialylation and the muscle atrophy and weakness.

18 204 included patients developed ICU-acquired weakness.

19 is characterised by muscle inflammation and weakness.

20 rized by muscle degeneration and progressive weakness.

21 ean medicinal plant used to treat for muscle weakness.

22 hy (DMD) patients to slow the progression of weakness.

23 serum creatine kinase but no or minor muscle weakness.

24 o exhibit childhood-onset progressive muscle weakness.

25 ank assessment of its relative strengths and weaknesses.

26 ases, where the cytoskeleton exhibited local weaknesses.

27 dies to date have significant methodological weaknesses.

28 Future research should address these weaknesses.

29 ction methods exist, each with strengths and weaknesses.

30 RPF) to reveal their relative strengths and weaknesses.

31 ited understanding of relative strengths and weaknesses.

32 life span, yet propose a theory with several weaknesses.

33 se networks, each with its own strengths and weaknesses.

34 ing platforms and review their strengths and weaknesses.

35 igh RoB, mainly due to analysis or reporting weaknesses.

36 (42%), tremor (38%), aphasia (35%) and focal weakness (11%).

37 enty-six patients (71%) with functional limb weakness, 31 (67%) neurological and 23 (61%) healthy con

38 dred and seven patients with functional limb weakness, 46 neurological and 38 healthy control subject

39 type with facial weakness or scapular girdle weakness, 6.7% display minor signs such as winged scapul

40 ing that variable gearing may explain muscle weakness after stroke.

41 ing that variable gearing may explain muscle weakness after stroke.

42 PI3Kdelta inhibitors are nonoptimal, showing weakness against at least one of the several important p

43 onstrated the substantial muscle wasting and weakness, along with disruption of muscle's oxidative me

44 Aortic wall weakness and abnormal aortic hemodynamic profiles predis

45 to profound intellectual disability, muscle weakness and abnormal tone, autistic features, behaviora

46 as a congenital myopathy with marked facial weakness and additional clinical and pathologic features

47 myopathies characterized by skeletal muscle weakness and an increase in the number of central myonuc

48 evaluate the association of post-ICU muscle weakness and associated trajectories of weakness over ti

49 Ca(2+) release channel (RyR1) display muscle weakness and atrophy, but the underlying mechanisms are

50 nal degeneration in CMT causes distal muscle weakness and atrophy, resulting in gait problems and dif

51 opathies characterized by distal limb muscle weakness and atrophy.

52 These results highlight how plantarflexor weakness and contracture may contribute to observed gait

53 in the ankle plantarflexor muscles, such as weakness and contracture, occur commonly in conditions s

54 To elucidate the effects of weakness and contracture, we systematically introduced i

55 itating disorders that result in progressive weakness and degeneration of skeletal muscle.

56 Survivors report chronic skeletal muscle weakness and development of new functional limitations t

57 ventilation are at risk for profound muscle weakness and disability.

58 ally characterised by progressive asymmetric weakness and electrophysiologically by partial motor con

59 Skeletal muscle weakness and eventual muscle degradation due to loss of

60 ent to patients suffering from severe muscle weakness and exercise intolerance.

61 eshifting mutation complained of mild muscle weakness and fatigability.

62 he incidence of intensive care unit-acquired weakness and intensive care unit-related complications s

63 tive disorder that causes progressive muscle weakness and is the leading genetic cause of infant mort

64 N/CMT2 with slowly progressive distal muscle weakness and musculoskeletal deformities.

65 osis, swallowing difficulties, proximal limb weakness and nuclear aggregates in skeletal muscles.

66 hy characterized by ataxia, skeletal muscles weakness and numbness of the extremities in exposed huma

67 or neuron (MN) loss, which results in muscle weakness and often infantile or childhood mortality.

68 applicable for treating more general muscle weakness and possibly other conditions that result from

69 ophin protein, leading to progressive muscle weakness and premature death due to respiratory and/or c

70 racterized by progressive muscle wasting and weakness and premature death.

71 f improving muscle function in conditions of weakness and premature muscle fatigue.

72 l muscle atrophy, often with foot deformity, weakness and sensory loss.

73 e diseases of the peripheral nerves, causing weakness and sensory symptoms.

74 irment to AD associating with ongoing muscle weakness and the onset of muscle atrophy.

75 ighlight what we feel are the main points of weakness and the types of evidence that could be provide

76 existence of these two forms of ICU-acquired weakness and their impact on outcome.

77 Data herein details the muscular weakness and wasting exhibited by D2.mdx skeletal muscle

78 disorder characterized by progressive muscle weakness and wasting.

79 erized by slowly progressive skeletal muscle weakness and wasting.

80 rticipants had moderate to severe upper-limb weakness and were randomised to 6-weeks intensive physio

81 , delineating their respective strengths and weaknesses and describing potential drug targeting strat

82 Weaknesses and strengths of varying methods are presente

83 m study designs with different strengths and weaknesses and transdisciplinary collaboration will be v

84 nical features (finger flexor and quadriceps weakness) and pathological features (invasion of myofibr

85 betes mellitus, erectile dysfunction, muscle weakness, and all-cause mortality.

86 neurological findings of myoclonus, ataxia, weakness, and autonomic instability.

87 rogressive general fatigue, fluctuating limb weakness, and difficulty climbing stairs.

88 m, resulting in exercise intolerance, muscle weakness, and myocyte apoptosis.

89 d members presenting with adult-onset muscle weakness, and we provide clinical, metabolic, histologic

90 ich can be used to understand the strengths, weaknesses, and biases in the conservation effectiveness

91 and provides insights into their strengths, weaknesses, and long-term dynamics in terms of basins of

92 Accordingly, we review the strengths, weaknesses, and therapeutic implications of each model s

93 icted effects include energy deficit, muscle weakness, anomalies in cranial and skeletal development,

94 riage and during hospitalization were fever, weakness, anorexia, and diarrhea, although 21% of patien

95 Loss of skeletal muscle mass and muscle weakness are common in a variety of clinical conditions

96 Methodological strengths and weaknesses are also highlighted.

97 Weaknesses are the limited assessment of the role of den

98 plications, each with distinct strengths and weaknesses, are available for distance-matrix based anal

99 ving hSOD1/rag2 mice is preceded by muscular weakness as early as one month before death.

100 t their reliance on shared EPS may also be a weakness as social evolution theory predicts that inhibi

101 us Statement, we summarize the strengths and weaknesses as well as the future technological potential

102 zed by progressive lower-limb spasticity and weakness, as well as frequent bladder dysfunction.

103 of clinical conditions with both wasting and weakness associated with an impairment of physical funct

104 11 and a transient aphasia with right-sided weakness at the age of 30.

105 The symptoms of ANM include muscle weakness, atrophy, contracture and tremors accompanied b

106 for the prevention of bone disorders, muscle weakness, autoimmune diseases, and possibly also differe

107 s characterised by fever, myoclonus, ataxia, weakness, autonomic instability, and full recovery in mo

108 se increase (five [1%]), colitis, and muscle weakness (both four [1%]).

109 We discuss their strengths and weaknesses, both for fidelity to the underlying continuu

110 The mice demonstrated skeletal muscle weakness but did not experience early mortality.

111 isplayed significant atrophy and contractile weakness, but lacked impaired mitochondrial respiration

112 F1A2-deficient zebrafish had skeletal muscle weakness, cardiac failure and small heads.

113 thy (MFM) associated with progressive muscle weakness, cardiomyopathy, and respiratory failure.

114 al UPR activation effectively reduces muscle weakness caused by ethanol exposure.

115 Severe PF weakness caused the model to adopt a slower, "heel-walki

116 This article outlines key strengths, weaknesses, challenges, and opportunities for standardiz

117 lth outcome in patients with functional limb weakness compared to neurological disease and healthy co

118 creased in patients who develop ICU-acquired weakness compared with patients who do not develop ICU-a

119 cted repair, has complementary strengths and weaknesses compared to base editing, and induces much lo

120 ion, suggesting that quantitative BCR signal weakness contributes to restraint of IgE B cell response

121 characterized by severe, often fatal muscle weakness due to loss of motor neurons.

122 l sclerosis (ALS) presents with focal muscle weakness due to motor neuron degeneration that becomes g

123 d lattices have well known shear and fatigue weaknesses due to their periodic basis/structure.

124 Eleven patients with functional limb weakness, eight neurological control subjects and one he

125 or systemic risk, enable monitoring how such weakness emerges and progresses in real time.

126 dulthood), myopathic facies and marked axial weakness, especially of neck flexion, while limb muscles

127 Patients experience muscle pain, weakness, fatigue, and atrophy, but the underlying mecha

128 resents with cardiomyopathy, skeletal muscle weakness, fatigue, and other symptoms, probably all rela

129 ental status change (91%), at least 1 ocular weakness finding (84%), and neuroimaging without acute c

130 tarts to decrease before the onset of muscle weakness, followed by the emergence of hand tremor, a pr

131 We show that sepsis survivors have profound weakness for at least 1 month, even after recovery of mu

132 alysis of five patients with skeletal muscle weakness for whom heterozygous mutations within ANO5 wer

133 e simulation and analyze their strengths and weaknesses for future developments.

134 icospinal drive contribute to the pronounced weakness found in triceps.SIGNIFICANCE STATEMENT Althoug

135 found in one patient in the functional limb weakness group (1%) and in one neurological control (2%)

136 ed in 20% of patients in the functional limb weakness group and in 18% of the neurological controls (

137 Weakness had completely remitted in 20% of patients in t

138 diagnostic sensitivity, but its simultaneous weakness has been a lack of specificity due to diverse p

139 A weakness has been the unavailability of methods capable

140 te whether patients who develop ICU-acquired weakness have a different pattern of systemic inflammato

141 ted ability to therapeutically exploit their weaknesses, have been limiting factors in realizing the

142 She reported additional symptoms of weakness, headache, and arthralgia primarily involving h

143 Weakness, hyporeflexia, and electrophysiologic abnormali

144 s modularity and flexibility, and addressing weaknesses identified in the error analysis.

145 ts, which persisted in 3 at 4 months; facial weakness in 3 patients, which persisted in 1 at 4 months

146 n and might be expected to show preferential weakness in ALS.

147 tratifying progression of respiratory muscle weakness in amyotrophic lateral sclerosis (ALS) would id

148 ctive than IFN-alpha, suggesting a potential weakness in antiviral immunity.

149 with numbness of the right hand, progressive weakness in both lower limbs and weight loss.

150 inflammatory therapy to alleviate the muscle weakness in DMD patients.

151 tory pressure (PI(MAX)) reflects inspiratory weakness in late-onset Pompe disease (LOPD).

152 .8); tremors (RR, 7.5; 95% CI, 1.9 to 29.9); weakness in legs (RR, 8.1; 95% CI, 2.5 to 26.4); severe

153 mpted to point out its areas of strength and weakness in light of the published scientific literature

154 its role and mechanisms of action on muscle weakness in other conditions remains to be investigated.

155 ver therapy for intensive care unit acquired weakness in patients.

156 construct validity, and criterion validity; weakness in reliability.

157 manifest diaphragm muscle fiber atrophy and weakness in the absence of mitochondrial dysfunction and

158 ed by pouches (that is, diverticulae) due to weakness in the bowel wall, which can become infected an

159 lar dystrophy and leads to asymmetric muscle weakness in the facial, scapular, trunk and lower extrem

160 ith patients who do not develop ICU-acquired weakness in the first 4 days after ICU admission.

161 sensory ataxia, ocular, and/or bulbar motor weakness in the presence of a monoclonal IgM reacting ag

162 mutant animals did not display gross muscle weakness in vivo.

163 scular disease leading to progressive muscle weakness in which fatigue occurs and affects quality of

164 If diseases in nature arise because of weaknesses in holobiont physiology, instead of the virul

165 microbiota of the host, has underscored the weaknesses in our current treatment paradigm for UTIs.

166 esults can be used to identify strengths and weaknesses in residents' decision-making skills and yiel

167 The existing LCIA models present weaknesses in terms of the impact drivers considered, ge

168 With null measurements, we identified weaknesses in the approaches commonly used.

169 Our work demonstrates weaknesses in the simple general framework for understan

170 dge but also emphasize misunderstandings and weaknesses in this literature with the hope of triggerin

171 -19 pandemic has shone a bright light on the weaknesses in US infectious disease surveillance and a b

172 The predominant pattern of muscle weakness included bilateral ptosis (non-fatigable in adu

173 st and open acknowledgement of strengths and weaknesses, including those of established geneticists.

174 c specificity for MCI 'non-progressors' is a weakness inherent in framing MCI primarily within a dete

175 cognitive deficits, depression, muscle pain, weakness, intolerance to exercise, and fatigue.

176 romuscular disease in which crippling muscle weakness is evident from birth.

177 Axial weakness is greater than limb weakness.

178 This weakness is overcome in modern biological systems by kin

179 Misdiagnosis in functional limb weakness is rare after long-term follow-up.

180 molecular pathways that lead to aortic wall weakness is required to identify biomarkers and therapeu

181 A further weakness is that sensor media themselves are assumed to

182 Localized or general muscle weakness is the predominant symptom and is induced by th

183 exhibit progressive muscle degeneration and weakness, leading to loss of ambulation and premature de

184 ciated with clinical complaints (arthralgia, weakness, loss of vitality, and being diabetic) and majo

185 Physical frailty, often defined as slowness, weakness, low physical activity, shrinking, and exhausti

186 Within patients, there was greater relative weakness (lower MRC score) in thumb abductors versus elb

187 Next, we predicted how muscle weakness may cause deviations from a normal walking moti

188 esthesia, hypoesthesia; n = 45, 100%), motor weakness (n = 18, 40%), ophthalmoplegia (n = 20, 45%), a

189 eeding (n=1 [2%]), diarrhoea (n=1 [2%]), and weakness (n=1 [2%]).

190 In addition to weakness, NEM6 patients have slow muscle relaxation, com

191 e compounds while overcoming the traditional weakness of amorphous drug delivery: physical instabilit

192 However, a weakness of current mass spectrometry (MS) based metabol

193 e and neonatal diseases, probably due to the weakness of health-care systems and services, as evidenc

194 ertrophic cardiomyopathy and skeletal muscle weakness of human IOPD, indicating its utility for evalu

195 cessarily in the in vivo assays, showing the weakness of in vitro systems in predicting antioxidant r

196 The major weakness of most knock-in JAK2V617F mouse models is the

197 tal muscle disease characterized by muscular weakness of proximal dominance, hypotonia, and respirato

198 all ages, which may account for the relative weakness of the human MOC reflex and the difficulty in d

199 ng to magnesium ions underpins a fundamental weakness of the INSTI pharmacophore that is exploited by

200 sign in ALS refers to observed preferential weakness of the lateral hand muscles, which is unexplain

201 t the same time, the SAXS data highlight the weakness of the secondary interface between the ACD dime

202 Mechanical weakness of the stem was ruled out as an explanation for

203 The weakness of this model is that it cannot explain why som

204 This discovery identifies a weakness of vaccinia virus and suggests a possible direc

205 f other agencies, analyzes the strengths and weaknesses of American Heart Association peer review pra

206 erall, by highlighting the strengths and the weaknesses of both types of methods we argue that both s

207 Finally, we identify strengths and weaknesses of callsets by stratifying performance accord

208 Thus, we identified metabolic weaknesses of chloroquine-resistant parasites and propos

209 summary provides a view of the strengths and weaknesses of current technologies, provides perspective

210 By scenario analysis, strengths and weaknesses of different measures were identified.

211 nction, allow us to assess the strengths and weaknesses of different network architectures, and lead

212 Our work highlights strengths and weaknesses of each algorithm and results in a recommenda

213 pacity measurement to identify strengths and weaknesses of each method.

214 key questions, as well as the strengths and weaknesses of each option.

215 A thorough appreciation of the strengths and weaknesses of each technique is critical when choosing t

216 alance the often-complementary strengths and weaknesses of each, while promoting human control and sk

217 The review will highlight the strengths and weaknesses of HPK1 as a candidate target for novel immun

218 iology of HRP2, as well as the strengths and weaknesses of HRP2-based diagnosis compared with alterna

219 In this Review, we describe the weaknesses of isolated SCr-based diagnoses, the clinical

220 e developments and discuss the strengths and weaknesses of live-cell imaging with antibody-based prob

221 in other cancers that may underline specific weaknesses of multiple myeloma cells.

222 In recognition of the weaknesses of overdiagnosis estimation methods based on

223 The strengths and weaknesses of past studies inform recommendations for fu

224 ng research efforts to overcome the inherent weaknesses of peptide drugs, in particular their poor ph

225 , is significantly limited by their inherent weaknesses of poor conductivity and stacked structure.

226 Long-read sequencing can overcome the weaknesses of short reads in the assembly of eukaryotic

227 n conclusion, we summarize the strengths and weaknesses of studies implicating selected variants in t

228 ome sequencing and discuss the strengths and weaknesses of the major RNA sequencing technologies as t

229 nderlying evidence, review the strengths and weaknesses of the many population genetic methodologies

230 al fibrillation, highlight the strengths and weaknesses of the models, and discuss the unmet needs in

231 Furthermore, we evaluate the current weaknesses of the PSC model and the directions open to r

232 ic effects of malnutrition and point out the weaknesses of these approaches for measuring economic lo

233 We showed the strengths and weaknesses of these assemblers in terms of integrity, co

234 ng T cell activation is also one of the main weaknesses of this strategy as it may lead to systemic T

235 We also highlight some of the major weaknesses of this study that hinder efforts to accurate

236 tion with the pentavalent vaccine to capture weaknesses of vaccine management at the different levels

237 tic risk with current methods, strengths and weaknesses of various approaches, assessments of utility

238 n this Review, we describe the strengths and weaknesses of widely used computational approaches, expl

239 inpoint the specific features, including the weaknesses, of various tumor models, and to discuss the

240 isted in 3 and 1, respectively, at 4 months; weakness on the treated side in 5 patients, which persis

241 vents included speech and gait disturbances, weakness on the treated side, and dyskinesia.

242 iness community (which stands for strengths, weaknesses, opportunities, and threats) and applied this

243 Here, we use a Strengths-Weaknesses-Opportunities-Threats (SWOT) framework to cri

244 mild, moderate, and severe levels of muscle weakness or contracture to either the soleus (SOL) or ga

245 1,500 patients with unclassified limb girdle weakness or hyperCKemia for pathogenic POPDC3 variants.

246 by the sudden uncontrollable onset of muscle weakness or paralysis during wakefulness.

247 .1% present incomplete phenotype with facial weakness or scapular girdle weakness, 6.7% display minor

248 he patient denied chest pain, dyspnea, focal weakness, or prior similar episodes.

249 scle weakness and associated trajectories of weakness over time with 5-year survival.

250 motor neuron diseases associated with muscle weakness, paralysis and respiratory failure.

251 ed in a larger proportion of functional limb weakness patients (P = 0.011).

252 protein 2 is down-regulated in ICU-acquired weakness patients and mice with inflammation-induced mus

253 pathways enriched in muscle of ICU-acquired weakness patients, a gene set enrichment analysis of our

254 vation in vastus lateralis from ICU-acquired weakness patients.

255 articles and included transient facial nerve weakness, persistent blue dye staining of the conjunctiv

256 Outcome of limb weakness, physical and psychiatric symptoms, disability/

257 nd 2D approaches have relative strengths and weaknesses, related to the inherent sensitivity and reso

258 Deciphering mechanisms of muscle weakness requires sophisticated force protocols, dissect

259 (CMS) are characterized by fatigable muscle weakness resulting from impaired neuromuscular transmiss

260 It included early onset axial and proximal weakness, scoliosis, rigid spine, dysmorphic facies, cut

261 of sepsis can reproduce the long-term muscle weakness seen in patients who survive this life-threaten

262 ty, 94%; LR, 5.7 [95% CI, 1.6-20]), abductor weakness (sensitivity, 44%; specificity, 90%; LR, 4.5 [9

263 uring infancy, profound hypotonia and muscle weakness, severe intellectual disability and progressive

264 rm of spastic paraplegia resulting in muscle weakness, short stature, and cognitive defects.

265 er after prodromal symptom onset, had milder weakness, showed more rapid improvement, and were more l

266 sed in several complex cases such as zonular weakness, subluxated lens and traumatic cataracts becaus

267 ng arthralgia, bone pain, generalised muscle weakness, syncope, and dyspnea.

268 pathological age-related muscle wasting and weakness termed sarcopenia, which directly impacts physi

269 nifests in adulthood with proximal and axial weakness that progresses to involve distal muscles and c

270 disorder responsible for proximal lower limb weakness that subsequently expanded to the upper limbs,

271 rimental research methods have strengths and weaknesses that are largely complementary.

272 threatening their economic viability or the weaknesses that prevent their commercial implementation

273 Because of these weaknesses, the theory cannot explicate how individuals

274 les, the information provided, strengths and weaknesses, the types of samples that can be analyzed, a

275 However, current scenarios have a key weakness: they typically focus on reaching specific clim

276 y decoded sentences and hence identify model weaknesses to guide future model development.SIGNIFICANC

277 end users to identify program strengths and weaknesses to plan for wider dissemination and implement

278 reich's ataxia (FRDA) include ataxia, muscle weakness, type 2 diabetes and heart failure, which are c

279 ement, and proximal as well as distal muscle weakness (typical CIDP).

280 stroke patients, with plantar flexor muscle weakness, using a randomized controlled crossover design

281 The pattern of weakness varied widely, and the classic pontobulbar pals

282 ICU and hospital mortality, and limb muscle weakness was associated with longer duration of MV and h

283 mylpfa mutant muscle weakness was most pronounced in an appendicular muscle a

284 Mild skeletal myopathy/proximal muscle weakness was noted in 6 (29%) patients.

285 Muscle weakness was proximal with adulthood onset in most patie

286 lineate mechanisms of sepsis-induced chronic weakness, we first surpassed a critical barrier by estab

287 In an effort to understand its strengths and weaknesses, we performed a series of experiments with sy

288 pital with acute abdominal pain, generalized weakness, weight loss, and pyrexia.

289 Additional metabolic weaknesses were found in glutathione generation and lipi

290 type with typical facial and scapular muscle weakness, whereas 20.1% present incomplete phenotype wit

291 ntation of flaccid and often profound muscle weakness (which can invoke respiratory failure and other

292 her the two have complementary strengths and weaknesses, which synergize when combined to sharpen gen

293 ition, but they have different strengths and weaknesses, which we discuss in detail.

294 showed adult onset asymmetric distal muscle weakness with initial involvement of ankle dorsiflexion

295 ), a muscle disorder characterized by muscle weakness with limited treatment options.

296 hildhood very slowly progressive limb-girdle weakness with rigid spine and disabling contractures.

297 A weakness with this approach arises when melting overhang

298 l ophthalmoplegia, and generalized symmetric weakness without upper motor neuron signs.

299 These studies detail a primary muscle weakness (without a loss of muscle mass) in patients wit

300 el model of plant infection probing pathogen weaknesses; yet, the hierarchy of molecular events contr